Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) by Liperoti, Rosa et al.
 Current  Neuropharmacology, 2008, 6, 117-124 117
  1570-159X/08 $55.00+.00  ©2008 Bentham Science Publishers Ltd.
Antipsychotics for the Treatment of Behavioral and Psychological   
Symptomsof Dementia (BPSD)
Rosa Liperoti
1, Claudio Pedone
2 and Andrea Corsonello
3,4,*
1Centro di Medicina dell'Invecchiamento, Dipartimento di Scienze Gerontologiche, Geriatriche e Fisiatriche, Università 
Cattolica del Sacro Cuore, Largo A. Gemelli, I-00168 Rome, Italy; 
2Area di Geriatria, Università Campus BioMedico, 
Via dei Compositori, I-00100 Rome, Italy; 
3Fondazione San Raffaele, Cittadella della Carità, I-74100 Taranto, Italy; 
4Istituto Nazionale di Ricovero e Cura per Anziani (INRCA), I-87100 Cosenza, Italy 
Abstract: Behavioral and psychological symptoms of dementia (BPSD), i.e. verbal and physical aggression, agitation, 
psychotic symptoms (hallucinations and delusions), sleep disturbances, oppositional behavior, and wandering, are a com-
mon and potentially severe problem complicating dementia. Their prevalence is very high and it is estimated that up to 
90% of patients with Alzheimer’s disease (AD) may present at least one BPSD. Beside the obvious impact on the quality 
of life of people with dementia, BPSD are responsible for increased risk of patient institutionalization and increased costs. 
Furthermore, they are associated with caregivers’ stress and depression. Drugs used include antipsychotics, antidepres-
sants, anticonvulsivants, anxiolytics, cholinesterase inhibitors and N-methyl-D-aspartate receptor modulators. Among 
these, the most commonly used are anti-psychotics. These drugs have been used for many decades, but in the last years 
new compounds have been marketed with the promise of comparable efficacy but less frequent adverse effects (especially 
extra-pyramidal side effects). Their safety, however, has been challenged by data showing a potential increase in adverse 
cerebrovascular side effects and mortality. This review will summarize the pathophysiology and neuropharmacology of 
BPSD, it will describe the characteristics of the anti-psychotics most commonly used focusing on their efficacy and safety 
in BPSD.
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INTRODUCTION 
  Dementia is one of the most important problems in clini-
cal practice given the growth of elderly populations in the 
last decades [33]. While the hallmark of all dementia syn-
dromes is the decline of varying cognitive abilities, cognitive 
impairment should not be considered the only important 
symptomatology present in dementia. The term "behavioural 
and psychological symptoms of dementia" (BPSD) describes 
a wide spectrum of non-cognitive manifestations of demen-
tia, including verbal and physical aggression, agitation, psy-
chotic symptoms (hallucinations and delusions), sleep dis-
turbances, oppositional behavior, and wandering [7, 18].  
  BPSD are very frequent in dementia: up to 90% of pa-
tients with Alzheimer’s disease (AD) may present at least 
one of these symptoms, and it can be estimated that about 
one-third of AD patients have severe problems [10, 16, 45, 
61, 62]. Agitation, aggressiveness, wandering, oppositional 
behaviour and psychotic disorders are present in about 10-
50% of patients with AD, with a considerable impact on the 
functional status [8, 9, 14, 25, 26, 45, 54]. Indeed, these 
symptoms are very invasive and difficult to manage by the 
caregivers and the care teams [14, 16, 61].  
  BPSD may not be obvious during the early stages of AD, 
but these symptoms are also present in dementia syndromes 
other than AD, such as dementia with Lewy bodies or fronto-
temporal lobar degeneration [63, 68], where they may appear 
also in the early stages. Thus, the course of BPSD differ ac-
cording to the type of dementia [11, 20, 55]. Finally, the ap- 
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pearance of psychotic symptoms is a relevant risk factor for 
the development of aggressive behaviour and agitation, and 
is associated with a poorer functional prognosis [20, 54]. 
  Anyway, the appearance of BPSD during the evolution of 
any dementia syndrome represents a major management 
problem for both physicians and caregivers, and the evolu-
tion of these symptoms is the major reason for caregiver 
“burnout” and patient institutionalization, with an enormous 
increase in medical and indirect costs, and with a frequent 
decrease in quality of life for the patient and the caregiver [7, 
17, 33]. 
  The etiology of these symptoms is yet to be definitely 
clarified, and this certainly contributes to limit the pharma-
cological approach to BPSD. Nonetheless, it is conceivable 
that several factors including neurobiological, physical and 
environmental components are likely to be involved [7]. We 
will focus on the pathophysiological mechanisms underlying 
BPSD and the neuropharmacology of drugs used for the 
treatment of these symptoms, and we will also discuss the 
available evidence regarding the efficacy and the safety of 
conventional and atypical antipsychotics in patients with 
BPSD. 
PATHOPHYSIOLOGY OF BPSD 
  There is convincing evidence that the origin of BPSD in 
AD derives from identifiable anatomical and biochemical 
abnormalities. Given the wide array of psychopathologic 
symptoms in AD, however, it is unlikely that lesions of spe-
cific brain structure is related with a specific BPSD. Fur-
thermore, it is likely that baseline psychological factors are 
involved along with biological factors in the appearance of 
behavioural problems [65], although a retrospective bias can 
be in part responsible for the observed associations [79]. 118    Current Neuropharmacology, 2008, Vol. 6, No. 2 Liperoti et al. 
  Genetic studies show that chromosomal abnormalities are 
a risk factor for the development of BPSD. For example, a 
relationship between presenilin 1 and psychosis has been 
demostrated [39]. An association has also been shown be-
tween polymorphism of serotonin receptors genes (5HT2A
102-T/C and 5HT2C Cys23Ser) and visual and auditory hal-
lucinations, with the two polymorphisms having an additive 
effect on visual hallucinations [44]. Polymorphism of the 
dopamine receptors genes is also involved: in 275 outpa-
tients with probable AD, homozygous for DRD1 allele B1 
and homozygous for either DRD3 allele were both associ-
ated with psychosis [83].
  A genetic polymorphism of the serotonin transporter 
promoter region (L/L genotype) has been implicated with 
aggressive behaviour in patients with AD [81]. The same 
genotype seems to be associate with a distinctive phenotype 
characterized by psychotic symptoms and aggressive behav-
iour [84]. 
  The typical pathologic lesions of AD, neurofibrillary 
tangles (NFT), exhibit a characteristic distribution pattern 
that is correlated with dementia stage. In the earlier stages, 
there is an invasion from the enthorinal cortex to the hippo-
campus, while in more advanced stages there also is an in-
volvement of the neo-cortex [12]. While “negative” psychi-
atric symptoms (such as depression) can be evident even 
before a diagnosis of AD is made, “positive” symptoms (agi-
tation, aggressive behaviour) appear usually at later stages of 
dementia, after the appearance of cognitive abnormalities 
and presumably when the neo-cortex is invaded by NFT 
[47].  
  As can be expected, different behavioural problems re-
flect involvement of different cerebral areas. It has been 
shown that people with AD who develop psychosis have a 
2.3-fold greater density of NFT in the neo-cortex (middle 
frontal, anterior third of the superior temporal, inferior parie-
tal) compared to AD patients who will not develop psychosis 
[29]. Neurofunctional imaging studies have shown that psy-
chosis in probable AD is associated with a reduction in pre-
frontal, left frontal-temporal, and right parietal metabolism 
[61,82]. These evidences, however, come from studies with 
very small sample size. 
  Delusional misidentification (such as the belief that a 
close relative has been replaced by some other person having 
the same appearance) have been found to be correlated with 
lower neurone count in the CA1 area of the hippocampus; in 
the same study a lower neurone count in the dorsal raphe was 
associated with delusions and hallucinations [34].  
  Higher NFT concentration has been reported in the or-
bito-frontal cortex of AD patients with agitation [85], while 
single-photon emission CT demonstrated hypoperfusion of 
the left anterior temporal cortex in AD patients showing ag-
gressive behaviour [43]. Also in non-AD dementia, there 
seems to be an association between location of pathologic 
lesions and behavioural problems. In Lewy’s disease, for 
instance, it has been shown that there is a strong association 
between the density of Lewy’s bodies in the amygdala and 
parahyppocampal cortex and the presence of severe visual 
hallucination [38].  
PHARMACOLOGY OF ANTIPSYCHOTICS 
  As different cerebral regions are involved in the patho-
genesis of BPSD, different neurotransmitters have been 
found to be implicated in these disturbances (acetylcholine, 
dopamine, serotonine). Most pharmacologic treatment for 
BPSD are based else on drugs increasing the activity of these 
neurotransmitters (acetylcholine), or by decreasing or modu-
lating it (dopamine, serotonine). 
  For decades, the mainstay of treatment for psychosis in 
dementia have been the so-called “conventional” or first-
generation antipsychotics, that have been used since the ‘50s. 
There are three principal chemical classes of these drugs 
(phenotiazines, butyrophenones and thioxanthenes), and all 
of them share high affinity for the D2 dopamine receptor. 
The efficacy of these drugs is strictly correlated with the 
occupancy rate of D2 receptors: a PET study demonstrated 
that D2 occupancy predicted the clinical response to halop-
eridol, and that a threshold of 65% occupancy rate provided 
a good separation between responders and non-responders 
[50]. These results are consistent with others obtained with a 
different antipsychotic drug (raclopride) [70]. The occupancy 
of D2 receptors in the basal ganglia is also correlated with 
extra-pyramidal effects of these drugs [30, 70], as well as to 
other side effects such as hyperprolactinemia [50]. First-
generation anti-psychotics have been also shown to block D2 
receptors in the limbic cortical areas, and this activity seems 
to be most important in treating psychotic symptoms [89]. 
  Newer anti-psychotic drugs have been dubbed “atypical” 
because they seem to induce extra-pyramidal effects less 
frequently and because they seem to have therapeutic effi-
cacy in patients who do not respond to first-generation anti-
psychotics. 
  Clozapine is the prototype of this newer anti-psychotic 
agents. Its pharmacodynamic profile includes low affinity for 
both D1 and D2 dopamine receptors, along with high affinity 
for D4 dopamine receptor and serotonine receptors (5HT2 
and 3) [51]. It also has an anti-glutamatergic action [56], as 
well as alpha-2 receptor affinity and M1 cholinergic receptor 
blocking activity [28]. Dopamine receptors block by clozap-
ine is evident especially in the mesolimbic, but not in the 
nigro-striatal system [3], and this can in part account for the 
low incidence of extrapyramidal side effects. 
  Enhanced efficacy and reduced extra-pyramidal symp-
toms observed with second-generation anti-psychotic drugs 
have been explained with their high 5HT2/D2 activity [67]. 
More recently, the fast dissociation of “atypical” anti-
psychotics from the D2 receptor compared to older drugs has 
been proposed as the mechanism by which these drug have 
an anti-psychotic effect without extra-pyramidal effects or 
prolactine elevation [49]. Despite its seemingly optimal 
pharmacological profile, use of clozapine is not widespread 
because a consistent risk of agranulocytosis.  
  Risperidone has been marketed as an atypical antipsy-
chotic because of its 5HT2/D2 affinity ratio. However, it has 
been shown a similar proportion of D2 receptors occupied by 
risperidone and haloperidol [48]. Olanzapine was introduced 
shortly after risperidone, and has a pharmacologic profile 
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cal” anti-psychotic marketed, it has a chemical structure and 
multi-receptor activity similar to clozapine [72], and acts 
selectively in the limbic system [46]. Ziprasidone, although 
structurally different from other antipsychotics, also shows a 
high 5HT/D2 ratio, although its affinity for D2 receptors is 
high [32]. 
  Benzamides (sulpiride and amisulpiride) are highly selec-
tive antagonistis of dopamine at the D2 and D3 receptors 
with a preferential limbic activity. Besides this post-synaptic 
actions, it has been shown to antagonize the pre-synaptic 
receptors that modulate dopamine release [77]. 
  Aripiprazole is a newer antipsychotic agent with a 
mechanism of action that is different from both first and sec-
ond generation antipsychotics. It acts as a partial agonist at 
the D2 and 5HT1A receptors and as an antagonist at the 
5HT2A receptor, and is considered a “stabilizer” of the do-
pamine/serotonin system [15]. 
EFFICACY OF ANTIPSYCHOTICS 
  Conventional antipsychotics have been approved in the 
1950s mainly for the treatment of schizophrenia. Since then, 
these agents have been systematically used for the treatment 
of BPSD in spite of a substantial lack of scientific evidence 
supporting their use in dementia. Few trials investigating the 
efficacy of conventional agents for the treatment of BPSD 
have been conducted between the 1960s and the late 1980s 
[6, 60, 75]. These studies mainly focused on the effect of 
haloperidol and thioridazine. They were characterized by 
small sample sizes and possible lack of power. Data from 
these early studies showed a modest advantage of conven-
tional antipsychotics over placebo with a nearly 40% placebo 
response, and only 18% benefit over placebo in the meta-
analysis by Schneider et al. [75]. Also, according to some of 
these studies, the observed superiority of conventional antip-
sychotics over placebo would be limited to symptoms of 
aggression and it would be absent in other behavioural and 
psychotic symptoms [60]. 
  Atypical antipsychotics have been licensed in the 1990s 
and approved by The US Food and Drug Administration 
(FDA) exclusively for the treatment of schizophrenia. Rap-
idly after their introduction in clinical practice, these medica-
tions have become the new standard of care for BPSD due to 
their reported advantages over conventional agents, particu-
larly with respect to extrapyramidal symptoms (EPS) and 
tardive diskinesia [19, 35, 68]. Over the last decade, the off-
label use of atypical antipsychotics in dementia has been 
promoted by clinical practice guidelines although the limited 
number of clinical trials suggesting the efficacy of these 
agents in dementia [2, 37]. In the late 1990s, atypical agents 
accounted for more than 80% of antipsychotic prescriptions 
in dementia [37, 59]. To date 22 randomized placebo-
controlled trials have investigated the efficacy of atypical 
antipsychotics for the treatment of BPSD. Only eleven of 
these studies have been published in full at the time of com-
pletion of this review (Table 1). No data from double blind 
randomized clinical trials on patients with dementia are 
available for amisulpride, clozapine, sertindole, ziprasidone 
or zotepine. 
  Compared to placebo, risperidone has been shown to be 
beneficial on psychotic symptoms and aggression at doses of 
1 mg and 2 mg per day in three placebo controlled clinical 
trials [13, 23, 52]. These studies were conducted on patients 
with Alzheimer’s disease, vascular dementia or mixed de-
mentia on a 12 weeks time-period.  
  Olanzapine has been shown significantly effective for 
improving behavioural symptoms, psychosis and aggression 
at 5 to 10 mg per day dose compared with placebo [22, 80]. 
This evidence derives from two randomized placebo-
controlled clinical trials conducted among patients with de-
mentia for a 10 week and 6 week period of time respectively 
[22, 80]. In contrast with these data, a recent study on pa-
tients with moderate to severe psychotic symptoms of de-
mentia randomly assigned to receive a flexible dose of olan-
zapine (2.5-10.g per day), risperidone (0.5-2 mg per day) or 
placebo demonstrated similar improvement of BPSD in the 
three treatment groups with higher discontinuation rate due 
to adverse events in the olanzapine and risperidone groups 
[24].  
  Very recently, a 10-week, double- blind, placebo con-
trolled study has shown that quetiapine at a fixed dose of 200 
mg per day is effective and well tolerated for treating agita-
tion in institutionalized patients with dementia [90]. Also, 
one published study involving a small number of patients 
with dementia has demonstrated no effect of quetiapine or 
rivastigmine on improving clinically significant agitation and 
an increased cognitive decline associated with the use of 
quetiapine [4]. Finally, a small double-blind, placebo-con-
trolled, randomized study has shown no significant differ-
ence between quetiapine and placebo in terms of efficacy on 
controlling agitation and psychosis among patients with de-
mentia and parkinsonism [53]. In this study quetiapine was 
well tolerated and did not worse parkinsonism. As pointed 
out by the authors of this study, lack of power and a large 
placebo effect may have contributed to the resulted lack of 
efficacy.  
  A single double blind, randomized, placebo-controlled 
clinical trial has investigated the efficacy and safety of 
aripiprazole in patients with Alzheimer’s disease and psy-
chosis [21]. According to this 10-week study, aripiprazole at 
a mean dose of 10 mg per day appeared to confer no benefit 
over placebo for controlling delusions and hallucinations and 
it was well tolerated.  
  Very recently, the results of a large effectiveness trial, the 
CATIE-AD (Clinical Antipsychotic Trials of Intervention 
Effectiveness-Alzheimer’s Disease), have been published. 
According to this multicenter, double-blind, placebo-con-
trolled trial on outpatients with Alzheimer’s disease and psy-
chosis, aggression or agitation, the effect of olanzapine 
(mean dose 5.5 mg per day) and risperidone (mean dose 1.0 
mg per day) in treating neuropsychiatric symptoms was 
equally beneficial and superior to the effect of placebo and 
quetiapine (mean dose 56.5 mg per day) [76]. However, 
these benefits were evident only among those patients who 
tolerated these medications and did not discontinue them due 
to side effects. Similar rates of treatment discontinuation 
were reported in the different study groups. However, pa-
tients on antipsychotics discontinued mostly because of ad-
verse effects while patients on placebo discontinued mostly 
because of lack of efficacy. According to authors’ conclu-120    Current Neuropharmacology, 2008, Vol. 6, No. 2 Liperoti et al. 
sions potential side effect associated with antipsychotic 
medications in dementia may outweigh possible benefits.  
  A comprehensive review of the available randomized, 
double blind, placebo-controlled trials has been conducted 
by Ballard and White for the Cochrane collaboration to de-
termine the effectiveness of atypical antipsychotics for the 
treatment of psychiatric and behavioural symptoms in Alz-
heimer’s disease [5]. The authors analyzed sixteen placebo-
controlled trials among which only six studies were pub-
lished in full in peer reviewed journals. According to the 
Cochrane authors, evidence suggests that both risperidone 
and olanzapine may reduce aggression and risperidone may 
also reduce psychosis compared to placebo. However, an 
increased risk of extrapyramidal symptoms and adverse 
cerebrovascular events associated with atypical antipsychot-
ics would outweigh the modest effectiveness of these medi-
cations. According to Cochrane findings, due to the in-
creased risk of adverse effects, the use of atypical antipsy-
chotics in clinical practice would not be suitable and should 
be limited to those patients presenting with significant dis-
tress and risk associated with symptoms.  
SAFETY OF ANTIPSYCHOTICS 
  At the time of their introduction in clinical practice, 
atypical antipsychotics have been reported to be character-
ized by a better safety profile compared to conventional 
medications, especially with respect to extrapyramidal symp-
toms such as parkinsonism and tardive diskinesia. Data from 
clinical trials substantially confirm the superior EPS profile 
of atypical over conventional antipsychotics [13, 22, 23, 52, 
80]. Risperidone at dose of 1 mg per day has been proven to 
cause less EPS compared with placebo and haloperidol [13, 
23, 52]. However, this relative benefit of risperidone relative 
to haloperidol disappeared at dosages of 2 mg per day or 
higher [52]. In two randomized trials of olanzapine there was 
no increased incidence of EPS in the olanzapine groups (at 
Table 1.  Published Randomized Clinical Trials of Atypical Antipsychotics among Patients with BPSD 
Trial   Intervention  Daily Dose  Population  Setting  Duration 
(Weeks) 
Primary Efficacy 
Measure 
Katz, 1999 [52] risperidone vs placebo  Fixed, 0.5, 1.0 or 2.0 mg  N=625;  
AD, VaD, mixed 
Nursing 
home 
12 BEHAVE-AD 
De Deyn 1999 
[23]
risperidone vs haloperidol 
vs placebo 
Flexible, mean risperidone 
1.1 mg, mean haloperidol 
1.2 mg 
N=344;  
AD, VaD, mixed 
Nursing 
home 
13 BEHAVE-AD, 
CMAI, CGI 
Brodaty, 2003 
[13]
risperidone vs placebo  Flexible,  mean 0.95 mg  N=309;  
AD, VaD, mixed 
Nursing 
home 
12 CMAI, BEHAVE-
AD, CGI 
Street, 2000 [80] olanzapine vs placebo  Fixed, 5.0, 10.0 or 15.0 mg  N=206; AD  Nursing 
home 
6 NPI-NH 
De Deyn, 2004 
[22]
olanzapine vs placebo  Fixed, 1.0, 2.5, 5.0 or 7.5 
mg 
N=652; AD  Nursing 
home 
10 NPI-NH 
Deberdt, 2005 
[24]
olanzapine vs placebo vs
risperidone 
Flexible, mean olanzapine 
5.2 mg, mean risperidone 
1.0 mg 
N=298;  AD, VaD, 
mixed 
Outpatient 
and residen-
tial 
10 NPI,  CGI 
Ballard, 2005 
[4]
quetiapine vs rivastigmine 
vs placebo 
Flexible, range quetiapine 
50-100 mg 
N=93 ; AD  Nursing 
home  
26 CMAI,SIB 
De Deyn, 2005 
[21]
aripiprazole vs placebo  Fixed, 5, 10 or 15 mg  N=208; AD  Outpatient   10  NPI, BPRS 
Schneider, 2006 
[76]
olanzapine vs quetiapine 
vs risperidone vs placebo 
Flexible, mean olanzapine 
5.5 mg, mean quetiapine 
56.5 mg, mean risperidone 
1.0 mg) 
N=421; AD  Outpatient  36  Time from initial 
treatment to dis-
continuation/ 
CGIC
Zhong, 2007 
[90]
quetiapine vs. placebo  Fixed, 100 or 200 mg  N=333; AD  Nursing 
home 
10 PANSS-EC, CGI, 
NPI-NH, CMAI 
Kurlan, 2007 
[53]
quetiapine vs. placebo  Flexible, mean 120 mg  N=40; DLB, PD, 
AD
Outpatient 10  BPRS 
Abbreviations: AD= Alzheimer’s disease; VaD=Vascular dementia; DLB=Dementia with Lewy Bodies; PD= Parkinson disease with dementia; BEHAVE-AD=Behavioral Pathol-
ogy in Alzheimer’s disease rating scale; CMAI= Cohen-Mansfield Agitation Inventory; CGI=Clinical Global Impression; NPI= Neuropsychiatric Inventory; NPI-
NH=Neuropsychiatric Inventory –nursing home version; SIB= severe impairment battery; BPRS= Brief Psychiatric Rating Scale; CGIC=Clinical Global Impression of Change; 
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doses of 5 to 15 mg per day) compared with the placebo 
group. Observational data supported findings from clinical 
trials [22, 80]. Overall, the available evidence suggests that 
in dementia patients EPS are less frequently associated with 
atypical antipsychotics relative to conventional agents. How-
ever, parkinsonism and tardive diskinesia may be caused by 
atypical antipsychotics, especially at high dosages. 
  Beginning in 2002, warnings about a possible increased 
risk of cerebrovascular events (CVEs) and death among pa-
tients with dementia being treated with risperidone or olan-
zapine have been issued by drugs’ manufacturers and health 
regulatory agencies worldwide [31, 41, 87, 88]. These con-
cerns arose from the revision of both published and unpub-
lished clinical trials on atypical antipsychotics among pa-
tients with dementia. According to the results of these analy-
ses, risperidone was associated with a nearly 3-fold increase 
in the risk of CVEs in dementia patients [41]. The risk asso-
ciated with risperidone did not differ from the risk associated 
with placebo when serious CVEs including death, life threat-
ening or leading to permanent disability events were consid-
ered. Also, a nearly 2-fold increase in the risk of CVEs asso-
ciated with olanzapine was calculated but this estimate did 
not reach statistical significance [41]. More recently, a meta-
analysis of 15 randomized clinical trials on patients with 
dementia being treated with atypical antipsychotics reported 
a 65% increased all cause mortality associated with atypical 
antipsychotics compared with placebo [74]. In spite of this 
growing evidence from clinical trials, data from several large 
observational studies failed to support the conclusion of a 
possible increased risk of CVEs and death associated with 
atypical antipsychotics [36, 42, 57]. Moreover, a recent large 
retrospective cohort study suggested that conventional antip-
sychotics may indeed carry a nearly 40% excess risk of death 
compared with atypical agents and therefore they would not 
represent a valid alternative to atypical compounds for the 
treatment of BPSD [86]. According to the available evi-
dence, in April 2005, the FDA has issued a public health 
advisory to warn about a possible increased risk of death 
associated with atypical antipsychotics [31]. The FDA has 
asked manufacturers of these drugs to include a boxed warn-
ing in their labeling describing the risk and has reminded that 
atypical antipsychotics have not been approved for dementia 
which represents an off-label indication. The FDA has also 
anticipated a possible future extension of this warning to 
conventional antipsychotics.  
  Treatment with atypical antipsychotics among patients 
with dementia has been linked to some risk of lengthening of 
QTc interval at EKG [40, 78]. However, data available have 
suggested that atypical antipsychotics may not increase the 
risk of clinical outcomes related to QTc prolongation, includ-
ing ventricular arrhythmias and sudden death and with re-
spect to cardiac toxicity they may be safer than conventional 
medications [57, 71]. 
  Atypical antipsychotics are known to cause a spectrum of 
metabolic adverse effects such as diabetes, hyperlipidaemia 
and weight gain among young and adult patients with 
schizophrenia [66]. In particular, the risk of weight gain, 
diabetes and hyperlipidaemia has been reported high for clo-
zapine and olanzapine, moderately high for quetiapine and 
low for risperidone. To date, there is little evidence that pa-
tients with dementia being treated with atypical antipsychot-
ics may experience such metabolic effects [13, 22, 23, 52, 
80]. Also no data are available to investigate the extent to 
which such metabolic disturbances may contribute to the 
possible cardiovascular toxicity associated with atypical an-
tipsychotics. 
CONCLUSIONS 
  BPSD represent one of the main mental issues in the 
geriatric population. To date, limited evidence supports 
available therapeutic strategies and current recommendations 
mainly derive from consensus of experts [1, 7, 27]. Based on 
safety considerations and in light of the high rates of pla-
cebo-response in clinical trials, non pharmacological ap-
proaches are generally recognized as the first-line strategy 
for the treatment of BPSD. The pharmacological approach 
based on the use of antipsychotic medications is recom-
mended for the short-term treatment (up to three months) and 
among those patients who manifest severe symptoms that 
may cause extreme distress and harm to patients or others. 
Antipsychotic prescription is limited and strictly regulated in 
many countries and BPSD are still an off-label indication for 
most of these agents.
  In clinical practice, the therapeutic choice between atypi-
cal and conventional medications should be based on a care-
ful evaluation of the potential benefits and risks of both 
classes of antipsychotics as well as patients’ individual risk 
profile. Physicians should evaluate each patient individually 
and judge whether or not the magnitude of the potential risks 
outweighs the benefits that can be expected from the use of 
antipsychotics.
  Finally, evidence for potential pharmacological alterna-
tives to antipsychotics is also lacking. In the near future, re-
search efforts should be directed to investigate and identify 
alternative therapeutic strategies which may combine non 
pharmacological treatments with drug therapy and need to be 
tailored to patients with dementia and their families. 
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